Half-year report · HY
4671.TEDINET S100WYRV
Period2025-04-01 → 2025-09-30
Filed2025-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥21.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥43.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥21.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥1.1bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥974m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.0bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.3bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥803m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥794m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥803m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥794m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥36.4bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥36.0bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥36.2bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥11.1bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥10.8bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥25.3bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥25.3bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥25.9bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.0bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.4bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.5bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.4bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.6bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.1bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥73m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥860m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥79.87 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥181.81 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.46 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥79.66 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥180.81 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥74.25 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 69.3% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.4% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥266m |
| Clinical Testing Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥13.4bn |
| Clinical Testing Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥13.4bn |
| Clinical Testing Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| Clinical Testing Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥936m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥7.5bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥7.5bn |
| Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥241m |
| ICT Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥681m |
| ICT Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥681m |
| ICT Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥166m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥21.6bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥21.6bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥1.3bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥176m |
| Clinical Testing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥13.1bn |
| Clinical Testing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥13.1bn |
| Clinical Testing Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Clinical Testing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥726m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥7.7bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥7.7bn |
| Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥347m |
| ICT Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥538m |
| ICT Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥538m |
| ICT Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥76m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥21.4bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥21.4bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥1.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 524
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision for bonuses sga | Prior1InterimDuration | 204000000 | JPY |
| Provision for bonuses sga | InterimDuration | 206000000 | JPY |
| Retirement benefit expenses sga | Prior1InterimDuration | 61000000 | JPY |
| Retirement benefit expenses sga | InterimDuration | 55000000 | JPY |
| Welfare expenses sga | Prior1InterimDuration | 495000000 | JPY |
| Welfare expenses sga | InterimDuration | 549000000 | JPY |
| Depreciation sga | Prior1InterimDuration | 77000000 | JPY |
| Depreciation sga | InterimDuration | 149000000 | JPY |
| Rent expenses sga | Prior1InterimDuration | 260000000 | JPY |
| Rent expenses sga | InterimDuration | 228000000 | JPY |
| Supplies expenses sga | Prior1InterimDuration | 558000000 | JPY |
| Supplies expenses sga | InterimDuration | 515000000 | JPY |
| Amortization of goodwill sga | Prior1InterimDuration | 2000000 | JPY |
| Amortization of goodwill sga | InterimDuration | － | JPY |
| Miscellaneous expenses sga | Prior1InterimDuration | 181000000 | JPY |
| Miscellaneous expenses sga | InterimDuration | 166000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 13095000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 7732000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_jpcrp040300-ssr_E04982-000ICTBusinessReportableSegmentsMember | 538000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReportableSegmentsMember | 21366000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 21366000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E04982-000ICTBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_ReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -0 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 13095000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 7733000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E04982-000ICTBusinessReportableSegmentsMember | 538000000 | JPY |
| Net sales | Prior1InterimDuration_ReportableSegmentsMember | 21367000000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -0 | JPY |
| Net sales | Prior1InterimDuration | 21366000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 726000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 347000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E04982-000ICTBusinessReportableSegmentsMember | 76000000 | JPY |
| Operating income | Prior1InterimDuration_ReportableSegmentsMember | 1150000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -176000000 | JPY |
| Operating income | Prior1InterimDuration | 974000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 13416000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 7533000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E04982-000ICTBusinessReportableSegmentsMember | 681000000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 21630000000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 21630000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E04982-000ClinicalTestingBusinessReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E04982-000DispensingPharmacyBusinessReportableSegmentsMember | 0 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E04982-000ICTBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | 0 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |